Yax

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Yax

Quick Facts

Property Description
Active Ingredients Drospirenone and Ethinyl Estradiol
Form Oral Contraceptive Tablets (Film-coated)
Pharmacological Class Hormonal Contraceptives for Systemic Use
Common Use Pregnancy Prevention (Contraception)
Origin Synthetic hormones

What Type of Drug is Yax? (Identity and Classification)

Yax is a prescription-only medicine that is classified as a Combination Oral Contraceptive (COC), belonging to the high-level Hormonal Contraceptives for Systemic Use pharmacological class. It is supplied as oral contraceptive tablets which are administered orally in a structured daily regimen. The product is fundamentally defined by its precise structure as a fixed combination of two distinct synthetic hormones delivered together. This combination product is used for preventing pregnancy, a primary role that is clinically recognized across international guidelines as a highly effective form of birth control.

What is Yax Made Of? (Composition and Differentiation)

Yax is composed of two active ingredients by their non-proprietary names: Drospirenone and Ethinyl Estradiol. These are synthetic hormones formulated to exert systemic effects. Ethinyl Estradiol serves as the estrogen component, and Drospirenone is the progestin component. This specific formulation is distinguished by the unique nature of Drospirenone, which is derived from spironolactone, conferring it with secondary antimineralocorticoid activity. This structural difference has been supported by pharmacological studies for potentially influencing fluid retention compared to progestins lacking this activity. The tablets are film-coated and packaged to include both active tablets (containing the hormones) and inert tablets (placebos) to aid in maintaining the daily administration routine.

What is the General Purpose of Yax? (High-Level Benefit)

The general purpose of Yax is to provide highly reliable pregnancy prevention, serving as an effective method of contraception for women of reproductive potential. The effectiveness stems from the synergistic action of the fixed combination of hormones, which work through multiple physiological actions. These actions include the primary effect of inhibition of ovulation—stopping the monthly release of an egg—and secondary effects like thickening cervical mucus and altering the endometrium, which together ensure continuous and systemic reproductive control.

What side effects are possible with Yax?

Possible Side Effects and Safety Information

The safety profile of this combination oral contraceptive is characterized by officially documented common reactions and the low but serious risk of vascular events, as stated in regulatory documents.


Officially Documented Adverse Reactions

The assignment of frequency is based on data from controlled clinical trials. The most frequently observed adverse reactions (incidence 2%) include headache or migraine, nausea, breast tenderness or pain, and menstrual irregularities (breakthrough bleeding or spotting). Other common reported effects involve the psychiatric system, such as mood changes and irritability, and an increase in body weight.

System-Organ Class Involved Example Adverse Reactions (Common)
Reproductive/Breast Disorders Breast tenderness, menstrual irregularities
Nervous/Gastrointestinal Headache, nausea, vomiting
Psychiatric Disorders Mood changes, decreased libido

Serious Safety Considerations

The most significant and serious adverse events documented in official labeling concern thromboembolic disorders. These include the rare potential for Venous Thromboembolism (VTE), such as Deep Vein Thrombosis and Pulmonary Embolism, and Arterial Thromboembolism (ATE), encompassing stroke and myocardial infarction. The risk of VTE is officially noted as being highest during the first year of use or upon restarting after a break of four weeks or more.

Due to the specific progestin component, the drug carries a safety note regarding the risk of Hyperkalemia (high potassium levels). For this reason, official safety information specifies that the medicine is contraindicated in women with severe renal insufficiency or severe hepatic disease. The use is also restricted in women with uncontrolled hypertension or a history of migraine with focal neurological symptoms (aura), as these conditions may elevate the documented vascular risks.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents define the overdose profile for Yax based on documented manifestations and mandated emergency actions. All information is strictly derived from authoritative government sources, such as the U.S. FDA Prescribing Information.

Documented Overdose Manifestations

Domain Official Regulatory Statement
Overdose Presentations Overdose in females may result in nausea and withdrawal bleeding (or vaginal bleeding).
Physiological Risk The renal/metabolic system is affected, requiring monitoring for severe electrolyte imbalance (e.g., hyperkalemia) and metabolic acidosis due to the drospirenone component.
Exposure Considerations The overdose scenario includes the possibility of accidental ingestion by children.

Emergency Actions and Management

Domain Official Regulatory Statement
Immediate Action Seek immediate medical attention when an overdose is suspected. Call a Poison Help Line immediately.
Management Overdose is managed with symptomatic and supportive treatment.
Monitoring Required Monitoring of serum potassium and sodium concentrations is explicitly required due to the antimineralocorticoid risk of the drug.
Antidote No specific antidote is known for this combination oral contraceptive overdose.

The regulatory profile mandates urgent help-seeking based on the documented manifestations and the inherent physiological risk of electrolyte disturbance, ensuring timely supportive care and monitoring.

Therapeutic Uses of Yax

What Yax Treats: Main Uses and Benefits

Quick Fact: Support for Cyclical and Dermatological Symptoms

The medication is commonly used to help with pregnancy prevention, manage the symptoms of Premenstrual Dysphoric Disorder (PMDD), and assist with moderate acne vulgaris. This use supports the management of symptoms that interfere with daily functioning during cyclical or episodic changes.

The medication is commonly used to provide therapeutic support across three main symptomatic domains in women of reproductive potential, in clinical settings where supportive management of symptoms is appropriate. The medication is generally used to help manage these distinct conditions.

Pregnancy Prevention and Symptom Management

Yax is primarily used to support pregnancy prevention for females of reproductive potential. Beyond fertility control, this use assists with establishing more predictable, lighter menstrual cycles, which contributes to easing the overall symptom load related to heavy or irregular periods and associated discomfort.

Management in this therapeutic domain may assist with managing symptoms related to the severe mood and physical manifestations of PMDD, including pronounced anxiety, irritability, and fluid retention-related bloating that recur cyclically and interfere with daily functioning.

Treatment for Moderate Hormonally-Driven Acne

Yax is commonly used to help with moderate acne vulgaris in patients who also desire oral contraception. This application provides support that helps improve skin clarity by assisting with the management of acne lesions (both inflammatory and noninflammatory) across the face and sometimes the body. This is relevant for conditions where functional stability becomes affected by moderate acne.

Regulatory References

  1. NIH DailyMed

Eligibility and Restrictions for Use

Official Eligibility and Contraindications

Yax (Drospirenone/Ethinyl Estradiol) is officially approved for use in females of reproductive potential after the onset of menstruation who do not have any documented contraindications. Eligibility is strictly determined by ruling out specific high-risk medical conditions and demographic risk factors, as outlined in regulatory documentation.

Population Status Regulatory Rule (Non-Eligible Groups)
Absolute Contraindication Individuals with a current or history of thrombotic events (e.g., deep vein thrombosis, stroke, heart attack) or hereditary clotting disorders
Absolute Contraindication Females over 35 years of age who are current smokers (due to increased cardiovascular risk)
Absolute Contraindication Patients with uncontrolled hypertension, diabetes with vascular involvement, or severe migraine with aura
Organ/System Restriction Patients with severe hepatic impairment, renal insufficiency, or adrenal insufficiency
Physiological State Known or suspected pregnancy (contraindicated) and breastfeeding (use not recommended, may reduce milk supply)
Age Restriction Contraindicated before menarche and not indicated for post-menopausal women

Use is also prohibited for patients with a current or history of breast cancer or other hormone-sensitive tumors, as well as for those with undiagnosed abnormal uterine bleeding. The regulatory profile focuses on preventing use in populations where the risk profile is unacceptably high.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Yax defines interaction patterns based on metabolic pathways and pharmacodynamic effects.

Scope Element Officially Documented Information
Medicinal product categories with documented interactions Hepatic Enzyme Inducers; Hepatic Enzyme Inhibitors; Drugs that increase serum potassium (e.g., ACE Inhibitors, ARBs); Specific Hepatitis C drug regimens; Medicines sensitive to weak enzyme inhibition.
Interaction-related restrictions Strict contraindication exists for co-administration with Hepatitis C drug combinations containing Ombitasvir/Paritaprevir/Ritonavir, with or without Dasabuvir, due to the documented risk of liver enzyme elevation.
Population-specific interaction notes The pharmacodynamic risk of hyperkalemia requires particular caution and monitoring in individuals with pre-existing conditions that predispose to high potassium, such as Renal Impairment or Adrenal Insufficiency.

Official interaction statements

  • Substances that induce the CYP3A4 enzyme system, including certain antiepileptic medicines and the herbal product St. John's Wort, may reduce the exposure of the active hormones.
  • The co-administration of potassium-retaining agents creates a pharmacodynamic risk of hyperkalemia due to Drospirenone’s antimineralocorticoid activity.
  • Conversely, strong CYP3A4 inhibitors like Ketoconazole may increase the hormone exposure.

Regulatory documents define the product’s interaction structure primarily through pharmacokinetic mechanisms that modify hormone concentrations and pharmacodynamic risks associated with potassium retention. This framework officially establishes combinations that are prohibited and those that may alter drug exposure, as detailed in the official prescribing information.

Mechanism of Action

The mechanism of Yax involves the concerted action of Drospirenone and Ethinyl Estradiol across three distinct biological domains. The primary mechanism is mediated by both synthetic hormones acting as agonists at the Progesterone Receptors ( PR) and Estrogen Receptors ( ER). This receptor activation imposes a powerful negative feedback signal on the Hypothalamic-Pituitary-Ovarian ( HPO) Axis, suppressing the release of pituitary LH and FSH. This central mechanistic cascade results in Anovulation (Inhibition of Ovulation). Simultaneously, local agonistic effects modulate reproductive tract tissues, causing a thickening of the cervical mucus and a thinning of the uterine lining (endometrium), establishing secondary physical barriers. Drospirenone also exerts unique activity as an antagonist at the Mineralocorticoid Receptor ( MR) and Androgen Receptor ( AR). MR antagonism modulates the RAAS by promoting renal excretion of sodium and water, functionally leading to the modulation of renal sodium and water excretion. The AR antagonism, synergized by Ethinyl Estradiol's increase in SHBG, results in a decrease in bioavailable androgen receptor binding potential.

Dosage and Administration Information

Official Administration Protocol

Yax is administered orally as one tablet per day in a continuous daily regimen. The high-level usage pattern is defined by a structured, repeating 28-day cycle consisting of 24 consecutive active tablets followed by 4 consecutive inert tablets.

Administration Scope

Instruction Detail (Label-Based)
Route of administration Oral (by mouth).
Dosing schedule One tablet daily for 28 consecutive days.
Timing in relation to meals Must be taken at approximately the same time every day, without regard to meals.
Age-group administration rules For the acne indication, use is specified only for females at least 14 years of age who have achieved menarche.

Procedural Structure

The medicine is used sequentially, requiring the tablets to be taken in the exact order directed on the blister pack. The continuous nature of the 24 active / 4 inert structure dictates that a new 28-day pack must be started immediately after completing the inert tablets of the previous cycle. Official prescribing information details two procedural options for beginning the first course: the Day 1 Start or the Sunday Start method. If the Sunday Start is used, a non-hormonal back-up method must be used for the first seven days of the initial cycle. Furthermore, specific missed dose protocols exist for how to proceed if one or more active tablets are missed, with instructions varying based on the cycle week. This entire procedural framework establishes the required standardized, long-term administration structure.

Recent Clinical Evidence

Research evidence / Overview of studies for Yax

Evidence for Pregnancy Prevention

Research was studied for pregnancy prevention through pivotal clinical trials and large-scale observational studies. These studies monitored outcomes such as the annual rate of unintended pregnancy, often reported using the Pearl Index. The long-term monitoring of usage patterns contributes to the broader evidence landscape, tracking use over many years. The patterns described in the research was associated with consistent user compliance; comparative evidence against every alternative method is still emerging.


Evidence for Symptoms of PMDD and Moderate Acne

The product was evaluated in short-term (three-cycle), randomized, placebo-controlled trials for the severe symptoms related to Premenstrual Dysphoric Disorder (PMDD). Researchers examined outcomes related to systemic imbalance using validated patient-reported outcomes and scales (e.g., DRSP). Separately, research was studied for moderate acne vulgaris using intermediate-term (six-cycle) trials. These studies monitored outcomes through quantitative counting of acne lesions and qualitative assessment of skin appearance (ISGA).


Research Gaps and Uncertainty

Long-term outcomes or the durability of the reported changes beyond the short follow-up periods are not fully established for either PMDD or acne. The research for acne is specific to women who are also using the product for contraception. Comparative evidence is lacking for certain uses, and subgroup findings are uncertain for women with specific pre-existing health conditions. The results apply only to the populations studied; generalizability of findings to other groups is uncertain.

Key Studies & References

  1. DailyMed - DROSPYRENONE AND ETHINYL ESTRADIOL tablet (Official Prescribing Information)
  2. WHO ATC Code G03AA12: Drospirenone and ethinylestradiol (Anatomical Therapeutic Chemical Classification)

Frequently Asked Questions (FAQ)

Common questions about Yax (FAQ)

Q: How long does it typically take to notice the effect of Yax?

A: The time to establish the product's indicated effect is dependent on the starting regimen used. Official guidance indicates that a non-hormonal back-up method may be needed for the first seven days of the first cycle, depending on when the active tablets are started.


Q: What are the most commonly reported side effects people experience with Yax?

A: According to official clinical trial data, the most frequently observed adverse reactions (reported by 2% or more of participants) include headache, nausea, breast tenderness, menstrual irregularities, and an increase in body weight. These reports reflect the frequency of effects observed during the studies.


Q: Does Yax interact with common over-the-counter pain relievers?

A: Official prescribing information notes that certain medicines that can increase serum potassium levels are noted for caution when used with Yax. This group includes medicines like Nonsteroidal Anti-inflammatory Drugs (NSAIDs), which are common pain relievers, due to the potential risk of elevated potassium levels.


Q: Is it safe to take Yax if I am also taking vitamins or herbal supplements?

A: Official information advises that the active ingredients in Yax can be affected by certain herbal products, such as St. John's Wort. For this reason, regulatory documents state that the patient should inform their healthcare provider about all supplements, vitamins, and herbal products used.


Q: If Yax doesn't seem to be working for me after a few weeks, what should my expectation be?

A: It is common for some women to experience minor irregular bleeding or spotting during the first one to three monthly cycles as the body adjusts to the medication. Regulatory information indicates that if these issues persist after the initial period, consulting with a healthcare provider is noted.


Q: Is Yax the same type of medication as [similar common drug class name]?

A: Yax is officially classified as a Combination Oral Contraceptive (COC). This is a high-level pharmacological class that includes any medicine taken by mouth that contains a fixed combination of both estrogen and progestin synthetic hormones.


Q: If I stop taking Yax, will the condition immediately return?

A: Upon cessation of the active tablets, the natural ovarian cycle is anticipated to return, which means the primary effect of inhibiting ovulation discontinues. The body returns to its pre-treatment reproductive state.


Q: I've read that Yax interacts with alcohol; what exactly does 'interact' mean in this case?

A: Official regulatory documents have reported a minor interaction between Ethinyl Estradiol, one of the active ingredients, and alcohol (ethanol). Specific clinical guidance on the relevance of this minor interaction is typically not specified in patient-facing materials.


Q: Are there any specific foods I need to avoid while on Yax?

A: Yes, official regulatory information specifically advises that grapefruit or grapefruit juice should be avoided during treatment with Yax. This is because consuming grapefruit may increase the blood concentrations of the active ingredient Drospirenone.


Q: Does Yax have any known interaction with grapefruit juice?

A: Official documents caution that consumption of grapefruit or grapefruit juice may increase the blood concentrations of the active ingredient Drospirenone. This potential interaction is noted in the official prescribing information.


Q: What should I do if a non-serious side effect from Yax does not go away?

A: If common initial side effects, such as minor spotting or mild stomach upset, persist or do not resolve after the first few cycles, official regulatory guidance states that patients consult with a healthcare provider for follow-up.


Q: Can I take Yax if I have kidney problems?

A: Official documents state that Yax is contraindicated (prohibited) for use in patients with renal impairment, which means significant kidney problems. This restriction is due to the risk of high potassium levels, which can be affected by the drug.


Q: Is Yax appropriate for people with liver issues?

A: Official regulatory information specifies that Yax is contraindicated (prohibited) in patients who have a current or history of liver tumors or hepatic impairment (liver disease). This restriction is in place due to the way the hormones are processed by the liver.


Q: Does taking Yax affect the results of common blood tests?

A: The active ingredient Drospirenone has antimineralocorticoid activity. Official prescribing information advises that a blood test to check serum potassium concentration may be noted for monitoring during the first treatment cycle for women on long-term treatment with certain other medications.


Q: I heard Yax is a 'new generation' drug; what makes it different from older versions?

A: The progestin component, Drospirenone, is described in medical literature as a fourth-generation progestin. It is distinguished by its secondary antimineralocorticoid properties, which are associated with influencing water and sodium balance, and antiandrogenic properties.


Q: Can Yax cause weight gain or weight loss?

A: Clinical trial data frequently reported an increase in body weight (incidence 2%) as a commonly observed adverse reaction. Official safety information also documents weight loss as an uncommon event associated with the use of the product.


Q: Does Yax have a sedation effect?

A: The official safety profile documents somnolence (sleepiness or drowsiness) as an uncommon adverse reaction. This means it was observed in a small percentage of patients (incidence 0.1% to 1%) during clinical trials.


Q: If I am lactose intolerant, can I take Yax?

A: Official composition information for the tablets indicates that they may contain lactose monohydrate as an inactive ingredient. This is a common component in many tablet formulations.


Q: Is Yax known to cause problems with vision?

A: Official safety information documents rare, serious vascular events which can include a retinal vein occlusion. Separately, changes to vision, or discomfort with contact lenses, have also been noted as possible effects.


Q: Why do some patients report feeling dizzy when standing up while taking Yax?

A: The active ingredient Drospirenone has antimineralocorticoid activity, which influences fluid and sodium balance in the body. Dizziness and hypotension (low blood pressure) are documented as uncommon adverse reactions in the safety profile, which may be related to these effects.


Q: Can I use Yax if I have diabetes?

A: Official safety information advises that the medication may affect carbohydrate and lipid metabolism. Regulatory documents state that monitoring is advised for prediabetic and diabetic women who use the product.


Q: Are the studies on Yax published in major medical journals?

A: The research supporting the product's uses, including data from pivotal clinical trials, has been reviewed and discussed in scientific publications. This includes articles and reviews found within the NIH National Library of Medicine.

How should Yax be stored and disposed of?

How to Store and Dispose of Yax? (Official Regulatory Requirements)

To ensure Yax (Drospirenone and Ethinyl Estradiol) remains stable and effective, storage must adhere strictly to official regulatory guidelines.

Requirement Domain Official Regulatory Statement
Storage Temperature Store at 20 C to 25 C (68 F to 77 F) (Controlled Room Temperature); do not freeze.
Packaging Protection Keep the blister strips in the original carton to shield the tablets from moisture, excessive heat, and direct sunlight.
Child Safety The medicine must be kept out of the reach and sight of children at all times.
Disposal Protocol Do not dispose of via household wastewater or trash. Return all unused or expired medicine to a pharmacist or follow specific local regulatory collection programs to protect the environment.

These mandated conditions define how the product must be stored, protected, handled, and discarded, and must be followed until the expiry date stated on the carton.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Yax found in:

A-Z Index: